Literature DB >> 32997574

To Continue or Not to Continue? That Is the Question.

Marina Chiara Garassino1, Benjamin Besse2, Valter Torri3.   

Abstract

Year:  2020        PMID： 32997574     DOI： 10.1200/JCO.20.02191

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  1 in total

Review 1.  Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.

Authors:  Faraat Ali; Kumari Neha; Garima Chauhan
Journal:  Arch Pharm Res       Date:  2022-05-22       Impact factor: 4.946
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.